aTyr Pharma, Inc. develops clinical-stage biotechnology programs based on its proprietary tRNA synthetase platform. Its news centers on efzofitimod, a biologic immunomodulator in development for interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease.
Company updates commonly cover EFZO-FIT and EFZO-CONNECT study activity, FDA interactions, quarterly and annual financial results, research and development spending, healthcare conference presentations, and equity award grants under Nasdaq inducement rules.
aTyr Pharma (ATYR) announced a research collaboration with Albert Einstein College of Medicine to test ATYR2810 in pediatric osteosarcoma.
The collaboration will be led by Dr. Bang H. Hoang, Co-Director of Orthopaedic Oncology at Montefiore Einstein, whose research includes the role of neuropilin-2 (NRP2) in pediatric bone cancers. ATYR2810 is an antibody designed to block NRP2, a cell-surface receptor. The research will further development and testing of the antibody in preclinical studies, before human trials.
ATYR2810 has demonstrated anti-tumor effects in preclinical models of non-small cell lung cancer, triple-negative breast cancer, renal cell carcinoma and glioblastoma. It remains in preclinical development and has completed GLP toxicology testing in non-human primates and cGMP manufacturing, processes governed by laboratory and manufacturing quality standards.
aTyr Pharma (ATYR) announced a Journal of Biological Chemistry publication demonstrating anti-fibrotic effects of ATYR0101 in preclinical research.
ATYR0101 targets LTBP-1, a protein in the material surrounding cells, to trigger programmed death of myofibroblasts, cells involved in tissue scarring. In a bleomycin-induced lung fibrosis model, ATYR0101 reduced collagen content and Ashcroft score, a measure of lung scarring, compared with nintedanib as a control. The candidate has also demonstrated anti-fibrotic effects in lung and kidney fibrosis models. It is undergoing studies needed to support an investigational new drug application; aTyr expects to advance it into clinical testing in 2027.
aTyr Pharma (ATYR) announced FDA alignment on its planned Phase 3 efzofitimod study protocol for pulmonary sarcoidosis on September 24, 2026.
The global, randomized, placebo-controlled study is designed to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis and restrictive lung disease. Over 54 weeks, participants will receive either 5.0 mg/kg efzofitimod or placebo intravenously every three weeks for 17 doses. The primary endpoint is change in forced vital capacity, a measure of lung function, at week 48. A lung-symptom questionnaire score is a secondary endpoint at week 48.
In a subgroup analysis of the earlier Phase 3 EFZO-FIT study, patients with restrictive lung disease who received 5.0 mg/kg efzofitimod showed improvements in forced vital capacity and patient-reported outcomes compared with placebo. aTyr expects to begin study-related activities in the fourth quarter of 2026, focusing on U.S. and European regulatory submissions. Further development will require additional capital.
aTyr Pharma (Nasdaq: ATYR) updated the expected timing for U.S. FDA feedback on the protocol for its planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Based on FDA feedback, the company anticipates a regulatory response by mid-September 2026.
The planned 54-week, global, randomized, double-blind, placebo-controlled trial is expected to enroll up to approximately 372 patients on stable low-dose corticosteroids and/or background immunosuppressants. Patients will receive either 5.0 mg/kg efzofitimod or placebo intravenously every three weeks. The primary endpoint is change from baseline in forced vital capacity at week 48, with a key secondary endpoint of change in King’s Sarcoidosis Questionnaire-Lung score at week 48.
aTyr Pharma (Nasdaq: ATYR) reported second quarter 2026 results and announced a major program prioritization and corporate restructuring to focus on its lead asset, efzofitimod, in interstitial lung disease (ILD), including pulmonary sarcoidosis and SSc‑ILD. The company is awaiting FDA feedback by the end of August 2026 on the protocol for a planned global Phase 3 pulmonary sarcoidosis trial and has completed enrollment in the Phase 2 EFZO‑CONNECT study in SSc‑ILD, with topline data expected in Q1 2027.
The restructuring includes a workforce reduction of about 60%, CFO and General Counsel transitions effective September 30, 2026, and is expected to cut annualized operating expenses by roughly $13 million from Q4 2026. aTyr ended the quarter with $58.9 million in cash, cash equivalents, restricted cash and investments and, according to the company, expects this to fund current operations into late 2028, though additional capital will be needed to conduct the planned Phase 3 study.
aTyr Pharma (Nasdaq: ATYR) reported a post hoc subgroup analysis from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, focusing on 44 patients with prespecified restrictive lung disease (FVC percent predicted ≤ 80%, FEV1/FVC ≥ 0.7).
According to aTyr Pharma, patients receiving 5.0 mg/kg efzofitimod showed a placebo-adjusted week 48 change from baseline in FVC of 123.8 ml using a random coefficient regression model, along with improvements across multiple patient-reported outcomes including KSQ-Lung, KSQ-General Health, Fatigue Assessment Scale and Leicester Cough Questionnaire. Steroid reduction in this dose arm was similar to placebo, and efzofitimod was generally well tolerated. In June 2026, the company submitted to the FDA a protocol for a planned Phase 3 study in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, using FVC as the primary endpoint and KSQ-Lung as the key secondary endpoint.
aTyr Pharma (Nasdaq: ATYR) reported first quarter 2026 results and a corporate update. The company ended March 31, 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments.
aTyr will continue developing efzofitimod in pulmonary sarcoidosis, plans a new global Phase 3 trial after an FDA Type C meeting, and remains on track to complete enrollment in the Phase 2 EFZO-CONNECT SSc-ILD study in the first half of 2026.
aTyr Pharma (Nasdaq: ATYR) will participate in two investor conferences in New York in May and June 2026. Events include the RBC Capital Markets Global Healthcare Conference on May 20 with 1x1 meetings and the Jefferies Global Healthcare Conference on June 4 featuring a fireside chat.
A webcast and 90-day replay of the Jefferies presentation will be available on aTyr’s investor relations website.
aTyr Pharma (Nasdaq: ATYR) outlined its regulatory and clinical path for efzofitimod in pulmonary sarcoidosis after an FDA Type C meeting.
The company plans to submit an IND in June 2026 for a new global Phase 3 trial using FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
The 54-week, randomized, double-blind, placebo-controlled study is expected to enroll up to approximately 372 patients, with dosing every three weeks and stable background corticosteroid and/or immunosuppressant therapy.
aTyr Pharma (Nasdaq: ATYR) reported full-year 2025 results and a corporate update. The company ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. R&D expense was $60.2 million and G&A expense was $17.6 million.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, but 5.0 mg/kg efzofitimod showed clinical benefit on multiple secondary measures. A Type C meeting with the FDA is scheduled for mid-April 2026.